JP2022511390A5 - - Google Patents

Info

Publication number
JP2022511390A5
JP2022511390A5 JP2021517768A JP2021517768A JP2022511390A5 JP 2022511390 A5 JP2022511390 A5 JP 2022511390A5 JP 2021517768 A JP2021517768 A JP 2021517768A JP 2021517768 A JP2021517768 A JP 2021517768A JP 2022511390 A5 JP2022511390 A5 JP 2022511390A5
Authority
JP
Japan
Application number
JP2021517768A
Other languages
Japanese (ja)
Other versions
JP2022511390A (ja
JPWO2020106708A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/062198 external-priority patent/WO2020106708A1/en
Publication of JP2022511390A publication Critical patent/JP2022511390A/ja
Publication of JP2022511390A5 publication Critical patent/JP2022511390A5/ja
Publication of JPWO2020106708A5 publication Critical patent/JPWO2020106708A5/ja
Priority to JP2024175673A priority Critical patent/JP2025013348A/ja
Pending legal-status Critical Current

Links

JP2021517768A 2018-11-20 2019-11-19 分割インターロイキン模倣体およびその使用 Pending JP2022511390A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024175673A JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862770152P 2018-11-20 2018-11-20
US62/770,152 2018-11-20
PCT/US2019/062198 WO2020106708A1 (en) 2018-11-20 2019-11-19 Split interleukin mimetics and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024175673A Division JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Publications (3)

Publication Number Publication Date
JP2022511390A JP2022511390A (ja) 2022-01-31
JP2022511390A5 true JP2022511390A5 (https=) 2022-11-24
JPWO2020106708A5 JPWO2020106708A5 (https=) 2022-11-24

Family

ID=69500815

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021517768A Pending JP2022511390A (ja) 2018-11-20 2019-11-19 分割インターロイキン模倣体およびその使用
JP2024175673A Pending JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024175673A Pending JP2025013348A (ja) 2018-11-20 2024-10-07 分割インターロイキン模倣体およびその使用

Country Status (13)

Country Link
US (2) US12234572B2 (https=)
EP (1) EP3883956A1 (https=)
JP (2) JP2022511390A (https=)
KR (1) KR20210094531A (https=)
CN (2) CN112912388A (https=)
AU (1) AU2019384523B2 (https=)
BR (1) BR112021008985A2 (https=)
CA (1) CA3119472A1 (https=)
EA (1) EA202190593A1 (https=)
IL (1) IL283217A (https=)
MX (1) MX2021005593A (https=)
SG (1) SG11202103045SA (https=)
WO (1) WO2020106708A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP3810640A1 (en) * 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス,インコーポレーテッド T細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
EP4288548A4 (en) * 2021-02-05 2025-01-15 Dharmacon, Inc. FUSION PROTEINS FOR CRISPR-BASED TRANSCRIPTION REPRESSION
WO2023044318A2 (en) * 2021-09-15 2023-03-23 Neoleukin Therapeutics, Inc. Interleukin-2 receptor βeta (il-2rβ) binding polypeptides
CN118715024A (zh) * 2022-01-24 2024-09-27 诺夫免疫股份有限公司 用于细胞因子信号传导通路的选择性激活的组合物和方法
IL322524A (en) 2023-03-07 2025-10-01 Chugai Pharmaceutical Co Ltd Conditional receptor signaling via scaffolding protein
EP4722235A1 (en) * 2023-05-24 2026-04-08 Nantong Yichen Biopharma. Co. Ltd. Polypeptide, and conjugate and use thereof
TW202519542A (zh) * 2023-07-13 2025-05-16 美商奧特佩斯生化股份有限公司 經設計之細胞激素組合物及使用方法
WO2025212606A1 (en) * 2024-04-01 2025-10-09 Bio-Techne Corporation Synthetic il-2 polypeptides and conjugates, compositions, and uses thereof
WO2026039791A1 (en) * 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026078029A1 (en) * 2024-10-10 2026-04-16 F. Hoffmann-La Roche Ag Splitted interleukin-2 prodrugs and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1015080A (en) 1908-04-17 1912-01-16 George I Rockwood Apparatus for operating alarms or other devices.
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
GB0019638D0 (en) * 2000-08-09 2000-09-27 European Molecular Biology Lab Embl Peptide mimetics
MXPA03011158A (es) 2001-06-07 2004-02-27 Wyeth Corp Estructura de solucion de il - 13 y sus usos.
CN1930300A (zh) * 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
US20110020269A1 (en) 2007-05-08 2011-01-27 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for modifying t cell immune responses and inflammation
US9676871B2 (en) 2010-11-05 2017-06-13 Pfizer Inc. Engineered polypeptide conjugates and methods for making thereof using transglutaminase
US9428567B2 (en) 2010-12-22 2016-08-30 The Board Of Trustees Of The Leland Stanford Junior University Antagonists of interleukin-2 receptor
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US9777070B2 (en) 2014-04-30 2017-10-03 Pfizer Inc Anti-PTK7 antibody-drug conjugates
WO2016025385A1 (en) 2014-08-11 2016-02-18 Delinia, Inc. Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
AR105616A1 (es) 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
WO2018153865A1 (en) 2017-02-24 2018-08-30 Philogen S.P.A. Immunoconjugates with optimized linkers and orientation
ES2894731T3 (es) 2017-03-15 2022-02-15 Silverback Therapeutics Inc Compuestos de benzazepina, conjugados y usos de los mismos
EP3810640A1 (en) 2018-06-25 2021-04-28 University of Washington De novo design of potent and selective interleukin mimetics
EP3883956A1 (en) 2018-11-20 2021-09-29 University of Washington Split interleukin mimetics and their use
EP3883585A4 (en) 2018-11-20 2022-12-14 Innovative Cellular Therapeutics Holdings, Ltd. MODIFIED CELL EXPRESSING THERAPEUTIC AND USES THEREOF
JP2022553370A (ja) 2019-10-25 2022-12-22 ネオルーキン セラピューティクス,インコーポレイティド Il-2受容体作動薬の投与方法
US20230331858A1 (en) 2019-12-24 2023-10-19 Neoleukin Therapeutics, Inc. Combination therapy using an il-2 receptor agonist and an immune checkpoint inhibitor
CN111040981A (zh) 2019-12-26 2020-04-21 南昌大学 表达重组IL-2的重组大肠杆菌Nissle 1917及其功能验证方法
EP4121449A2 (en) 2020-03-16 2023-01-25 Neoleukin Therapeutics, Inc. Interleukin-2 receptor beta (il-2rb) binding polypeptides

Similar Documents

Publication Publication Date Title
JP2021528052A5 (https=)
BR112019017762A2 (https=)
BR112021017339A2 (https=)
BR112021018450A2 (https=)
BR112021017637A2 (https=)
BR112021017892A2 (https=)
BR112021017782A2 (https=)
BR112021017939A2 (https=)
BR112021017738A2 (https=)
BR112021008711A2 (https=)
BR112019016141A2 (https=)
BR112021017728A2 (https=)
AU2020104490A5 (https=)
BR112021018452A2 (https=)
BR112021017703A2 (https=)
BR112021018102A2 (https=)
BR112019016138A2 (https=)
BR112019016142A2 (https=)
BR112021017732A2 (https=)
BR112021017234A2 (https=)
BR112021017355A2 (https=)
BR112021018168A2 (https=)
BR112021018093A2 (https=)
BR112021012348A2 (https=)
BR112021018250A2 (https=)